First-in-Man Study: Safety and Efficacy of INC-1 Bare Metal Stent in the Novo Coronary Lesions.

NCT ID: NCT03375411

Last Updated: 2022-10-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-30

Study Completion Date

2019-01-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a First In Man study with the aim to know the safety and effectiveness of a novel bare metal stent (INC-1) in the treatment of de novo coronary lesions in patients with stable coronary angina and unique coronary lessions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The cost of performing a percutaneous coronary intervention is very variable since a large number of materials and human resources are considered, with the Stent cost being a fundamental factor; in developing countries, the cost this technology represents an important expense for the patient and the health system; which promotes the development of local technology to support the requirement of these devices.

Ischemic heart disease together with cerebral vascular events is the main cause of, adding 15 million deaths per year. Percutaneous revascularization is the gold standard choice in many of the variants of presentation of ischemic heart disease, the implantation of Stents is the most used method.

Nowadays more and more countries start their own research and development of novel devices in order to reduce cost.

Research question: Is the INC1 Bare Metal Stent safe and effective for the treatment of de novo coronary lesions in humans? Hypothesis: The INC1 Bare-metal Stent is safe and effective for the treatment of de novo coronary lesions in humans

The INC1 Bare metal Stent is a 70uCoCr

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stents Coronary Artery Disease Angioplasty Humans Coronary Angiography Angioplasty, Balloon, Coronary Treatment Outcome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

INC1-Bare metal stent

Percutaneous coronary implantation of the device (Stent INC-1) following the standard procedure of stent placement

Group Type EXPERIMENTAL

Stent INC1

Intervention Type DEVICE

Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Stent INC1

Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both genders.
* From 18 to 75 years
* Stable ischemic heart disease.
* Live less than 300 km from the Institution
* Single coronary artery disease with a single coronary lesion
* Stenosis of 50 to 90% of the lumen of the vessel to be treated.
* Lesions less than 20 mm long
* Reference lumen of the vessel to be treated greater than 2.5mm and less than 4.5mm

Exclusion Criteria

* Left main disease.
* Lesions greater than 90% of the lumen.
* Non-dilatable lesion with conventional balloons.
* Contraindication for dual antiplatelet therapy.
* Creatinine clearance less than 45ml / min.
* Calcification from moderate to severe.
* Multivessel coronary artery disease.
* Chronic total occlusion.
* Cardiogenic shock or hemodynamic instability.
* Left ventricular ejection fraction less than 30%.
* Valvular disease of moderate to severe.
* Coronary disease in bifurcation.
* Probable or definite presence of thrombus in the lesion.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GSE Biomedical

OTHER

Sponsor Role collaborator

Medstent SA de CV.

UNKNOWN

Sponsor Role collaborator

Instituto Nacional de Cardiologia Ignacio Chavez

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gian Manuel Jiménez Rodríguez

Clinical investigator assistant

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gian Manuel Jiménez Rodríguez

Role: PRINCIPAL_INVESTIGATOR

Interventional Cardiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Instituto Nacional de Cardiología

Mexico City, , Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Mexico

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17-1036

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MGuard Stent and Microcirculation
NCT03087175 COMPLETED NA